| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
|
N Engl J Med
|
2011
|
6.42
|
|
2
|
Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
|
AIDS
|
2007
|
5.97
|
|
3
|
Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance.
|
Lancet
|
2002
|
5.80
|
|
4
|
Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting.
|
J Acquir Immune Defic Syndr
|
2004
|
4.58
|
|
5
|
Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections.
|
Lancet
|
2004
|
4.13
|
|
6
|
Depletion of regulatory T cells in HIV infection is associated with immune activation.
|
J Immunol
|
2005
|
3.00
|
|
7
|
Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
|
Lancet
|
2013
|
2.61
|
|
8
|
Expanding HIV care in Africa: making men matter.
|
Lancet
|
2009
|
2.54
|
|
9
|
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda.
|
AIDS Patient Care STDS
|
2005
|
2.48
|
|
10
|
Antiretroviral treatment in resource-poor settings: clinical research priorities.
|
Lancet
|
2002
|
2.36
|
|
11
|
Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial.
|
Antivir Ther
|
2006
|
2.02
|
|
12
|
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
|
N Engl J Med
|
2014
|
2.00
|
|
13
|
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
|
Clin Infect Dis
|
2008
|
1.98
|
|
14
|
Scale-up of HIV treatment through PEPFAR: a historic public health achievement.
|
J Acquir Immune Defic Syndr
|
2012
|
1.78
|
|
15
|
T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection.
|
J Infect Dis
|
2005
|
1.63
|
|
16
|
Impact of HIV antiretroviral therapy on depression and mental health among clients with HIV in Uganda.
|
Psychosom Med
|
2012
|
1.58
|
|
17
|
High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
|
AIDS Res Hum Retroviruses
|
2004
|
1.58
|
|
18
|
Factors associated with intention to conceive and its communication to providers among HIV clients in Uganda.
|
Matern Child Health J
|
2012
|
1.50
|
|
19
|
Diminishing availability of publicly funded slots for antiretroviral initiation among HIV-infected ART-eligible patients in Uganda.
|
PLoS One
|
2010
|
1.35
|
|
20
|
Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.
|
PLoS One
|
2012
|
1.33
|
|
21
|
HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytolysis.
|
J Immunol
|
2006
|
1.26
|
|
22
|
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
|
AIDS
|
2007
|
1.26
|
|
23
|
A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda.
|
AIDS Patient Care STDS
|
2009
|
1.24
|
|
24
|
Factors associated with condom use among HIV clients in stable relationships with partners at varying risk for HIV in Uganda.
|
AIDS Behav
|
2010
|
1.19
|
|
25
|
Coinfection with Schistosoma mansoni is associated with decreased HIV-specific cytolysis and increased IL-10 production.
|
J Immunol
|
2005
|
1.17
|
|
26
|
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
|
AIDS Res Hum Retroviruses
|
2008
|
1.16
|
|
27
|
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
|
Antivir Ther
|
2010
|
1.15
|
|
28
|
Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors.
|
J Acquir Immune Defic Syndr
|
2007
|
1.13
|
|
29
|
Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa.
|
Curr Opin HIV AIDS
|
2013
|
1.12
|
|
30
|
Global threat from drug resistant HIV in sub-Saharan Africa.
|
BMJ
|
2012
|
1.11
|
|
31
|
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
|
Antivir Ther
|
2009
|
1.08
|
|
32
|
Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors.
|
J Virol
|
2004
|
1.07
|
|
33
|
Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
|
Clin Infect Dis
|
2012
|
1.07
|
|
34
|
First trial of the HIV-1 vaccine in Africa: Ugandan experience.
|
BMJ
|
2002
|
1.06
|
|
35
|
Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda.
|
PLoS One
|
2011
|
1.06
|
|
36
|
Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy.
|
Pediatr Infect Dis J
|
2011
|
1.05
|
|
37
|
Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.
|
AIDS Res Hum Retroviruses
|
2013
|
1.03
|
|
38
|
Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda.
|
J Psychosom Res
|
2010
|
1.03
|
|
39
|
Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity.
|
J Clin Virol
|
2008
|
0.99
|
|
40
|
The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda.
|
AIDS Res Ther
|
2009
|
0.98
|
|
41
|
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
|
AIDS Res Hum Retroviruses
|
2009
|
0.97
|
|
42
|
Mechanisms of apoptosis of T-cells in human tuberculosis.
|
J Clin Immunol
|
2005
|
0.97
|
|
43
|
Depression in the pathway of HIV antiretroviral effects on sexual risk behavior among patients in Uganda.
|
AIDS Behav
|
2012
|
0.97
|
|
44
|
Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults.
|
Clin Infect Dis
|
2003
|
0.97
|
|
45
|
Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study.
|
AIDS Res Treat
|
2012
|
0.97
|
|
46
|
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
|
PLoS One
|
2013
|
0.97
|
|
47
|
The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children.
|
AIDS
|
2010
|
0.96
|
|
48
|
Orphanhood predicts delayed access to care in Ugandan children.
|
Pediatr Infect Dis J
|
2009
|
0.94
|
|
49
|
Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition.
|
J Virol
|
2005
|
0.92
|
|
50
|
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
|
Malar J
|
2014
|
0.90
|
|
51
|
Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.
|
AIDS
|
2013
|
0.90
|
|
52
|
Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility.
|
Int J Infect Dis
|
2006
|
0.90
|
|
53
|
A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.
|
PLoS One
|
2010
|
0.89
|
|
54
|
Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.
|
J Antimicrob Chemother
|
2008
|
0.88
|
|
55
|
Response to antiretroviral therapy of HIV type 1-infected children in urban and rural settings of Uganda.
|
AIDS Res Hum Retroviruses
|
2012
|
0.86
|
|
56
|
Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection.
|
AIDS Res Hum Retroviruses
|
2006
|
0.84
|
|
57
|
Flat-line funding for PEPFAR: a recipe for chaos.
|
Lancet
|
2009
|
0.84
|
|
58
|
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
|
Pediatr Infect Dis J
|
2015
|
0.83
|
|
59
|
Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
|
Vaccine
|
2008
|
0.83
|
|
60
|
Lessons from Africa.
|
J Acquir Immune Defic Syndr
|
2010
|
0.83
|
|
61
|
HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.
|
AIDS Res Hum Retroviruses
|
2014
|
0.81
|
|
62
|
Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.
|
AIDS Res Hum Retroviruses
|
2013
|
0.80
|
|
63
|
A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child.
|
AIDS Res Hum Retroviruses
|
2010
|
0.80
|
|
64
|
HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa.
|
Lancet Infect Dis
|
2013
|
0.79
|
|
65
|
Opportunities for improving the efficiency of paediatric HIV treatment programmes.
|
AIDS
|
2015
|
0.79
|
|
66
|
Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.
|
BMC Infect Dis
|
2013
|
0.78
|
|
67
|
Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care.
|
AIDS
|
2012
|
0.78
|
|
68
|
Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.
|
Vaccine
|
2011
|
0.77
|
|
69
|
Need for review of prevention of mother-to-child transmission practice especially in discordant couples: a case of mother-to-child transmission of HIV during breast feeding by a mother who tested HIV negative antenatally.
|
AIDS
|
2007
|
0.77
|
|
70
|
Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
|
Pediatr Infect Dis J
|
2014
|
0.75
|
|
71
|
Highly active antiretroviral therapy.
|
BMJ
|
2004
|
0.75
|
|
72
|
HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in sub-Saharan Africa.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
73
|
The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
|
Am J Epidemiol
|
2015
|
0.75
|
|
74
|
A qualitative exploration of the impact of HIV and ART on social disruption and household continuity in Uganda.
|
Afr J AIDS Res
|
2011
|
0.75
|
|
75
|
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.
|
AIDS
|
2016
|
0.75
|
|
76
|
No need for apologies.
|
J Acquir Immune Defic Syndr
|
2011
|
0.75
|
|
77
|
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
|
Am J Trop Med Hyg
|
2006
|
0.75
|